Vivoryon Therapeutics AG (NL:VVY)
:VVY
Want to see NL:VVY full AI Analyst Report?
VVY Stock Chart & Stats
€1.45
-€0.02(-0.92%)
At close: 4:00 PM EST
€1.45
-€0.02(-0.92%)
Day’s Range― - ―
52-Week Range€1.20 - €1.84
Previous CloseN/A
Volume52.66K
Average Volume (3M)31.39K
Market Cap
€38.65M
Enterprise Value€32.99M
Total Cash (Recent Filing)€5.62M
Total Debt (Recent Filing)€108.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding29,614,338
10 Day Avg. Volume27,146
30 Day Avg. Volume31,394
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Small-molecule PipelineVivoryon's focus on oral small-molecule therapeutics for neurodegenerative and inflammatory diseases is a durable strategic position: it concentrates R&D resources on a clear mechanism-driven portfolio, supports straightforward development and manufacturing paths, and makes the assets attractive for long-term partnerships or licensing.
Low Financial LeverageVery low debt levels reduce near-term solvency risk and interest burden, giving management structural flexibility to pursue development milestones. For a clinical-stage biotech, low leverage preserves options to raise non-debt funding (partnering, equity) without an immediate debt overhang constraining strategic choices.
Reduced Operating Cash Burn In 2025A material reduction in operating cash burn year-over-year indicates management has had measurable success slowing cash depletion. Sustained lower burn improves runway, reduces near-term financing urgency, and increases the probability the company can execute key development milestones or secure better-partnering terms without immediate dilution.
Bears Say
No Recent Product RevenueAbsence of operating revenue leaves the company entirely dependent on external financing or partnerships for funding. This structural revenue gap elevates execution risk over the medium term: failure to secure financing or milestone payments would directly constrain R&D progress and the ability to complete pivotal trials.
Sharply Reduced Equity And AssetsA dramatic shrinkage of equity and total assets materially worsens the company's financial buffer. Reduced capital reserves limit flexibility to absorb development setbacks, increase sensitivity to funding shocks, and raise the likelihood that future financing will be dilutive or come with onerous terms, harming long-term execution.
Persistent Negative Cash FlowContinued negative operating and free cash flow is a structural weakness for a development-stage biotech: absent near-term revenue or a major partnership, ongoing cash deficits necessitate repeated external funding rounds. That dependency increases dilution risk and can interrupt program timelines if capital access tightens.
Vivoryon Therapeutics AG News
VVY FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.20 and its highest was €1.84 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €38.65M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Jun 17, 2026 which is in 46 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Apr 23, 2026. The company reported -€0.118 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.118.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.118 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.716%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in NL:VVY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Technical Analysis
Options Prices
Currently, No data available
---